Donate to Illuminate Contact TSF
Visit us on Facebook Visit us on Twitter Visit us on YouTube Visit us on Instagram Visit us on Linkedin Visit us on Tiktok

Choose Your Language:

¡Bienvenido Dr. Álvaro Cobo-Calvo!

Posted by: The Sumaira Foundation in News & Announcements

June 21, 2023 — The Sumaira Foundation is pleased to welcome Álvaro Cobo-Calvo, MD, PhD, of the Multiple Sclerosis Centre of Catalonia (CEMCAT) in Barcelona, Spain, to join TSF’s Medical Advisory Board. Dr. Cobo-Calvo is the first NMOSD/MOGAD expert to join TSF from Spain.

Álvaro Cobo-Calvo, MD, PhD

Alvaro Cobo-Calvo, MD, PhD, is a neurologist working at CEMCAT, Barcelona, Spain, where he is focused on the diagnosis and treatment of patients with NMOSD-like diseases and MOGAD.

In 2012, Dr Cobo-Calvo finished his neurology training program at Bellvitge University Hospital, Barcelona, Spain. In 2015, he completed his international PhD program at Barcelona University, Spain and Université Claude Bernard I de Lyon, France, focused on idiopathic myelitis and MOG antibodies. During this period, he also completed a four year-master in health epidemiology and one master degree in neuroimmunology. 

In 2017, he completed a two year-post-doctoral program at the Multiple Sclerosis Center of Lyon (Hôpital Pierre Wertheimer), France. Subsequently he got a two- year contract as a Clinical neurologist at the Referral French Centre of rare demyelinating diseases in Lyon, France (2018-2019) where he deepened his knowledge in the basic and clinical field of NMOSD, mainly by studying clinical and prognostic factors of patients with aquaporin-4 and myelin oligodendrocyte glycoprotein (MOG) antibodies. 

Since January 2020, he has been working at the Multiple Sclerosis Centre of Catalonia (Cemcat), Barcelona, Spain. His research is mainly focused on prognostic biomarkers of NMOSD and MOGAD.

Industry Partners

Community Partners

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.